1 / 20

Small change, big difference: the discovery of drug candidate for anti-Schistosomiasis japonicum

Explore the impact of Schistosomiasis Japonicum and the urgent need for effective treatments. Learn about the high prevalence in China, the limitations of current drug Praziquantel, and the groundbreaking research at Shandong University seeking new drug candidates. Discover the promising results of compound P96 in targeting different stages of the parasite. Follow the latest developments in this preclinical study towards a potential anti-Schistosomiasis breakthrough.

lfuller
Download Presentation

Small change, big difference: the discovery of drug candidate for anti-Schistosomiasis japonicum

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Small change, big difference: the discovery of drug candidate for anti-Schistosomiasis japonicum Shandong University , P.R.China Dequn Sun dequn.sun@sdu.edu.cn

  2. how is the schistosomiasis? three main schistosomes causedschistosomiasis Schistosoma mansoni Schistosoma japonicum Schistosoma haematobium

  3. schistosomiasis over the world

  4. How the Schistosoma affect the people and animals

  5. The schistosomiasis due to Schistosoma japonicum in china is highly harmful relatively neglected tropical disease, and it has long been a major public health problem in China and other subtropical countries schistosomiasis was endemic in 10 provinces, 100 million people are at risk of infection and over 10 million people were infected

  6. The only drug for schistosomiasis in clinically Praziquantel (PZQ) is currently the first choice of drug for treatment of Schistosoma mansoni and Schistosoma haematobium infection and is the only drug fortreatment of Schistosoma japonicum infection

  7. fatal defects of PZQ Has high activity to adult worms, butvery low efficacy against juvenile forms of schistosome Before PZQ can kill the adult worms, the worms already give eggs, therefore,PZQ can not cure the schistosomiasis completely,this is the only reason that schistosomiasis has currently become a lasting infectious diseases Actionmechanism/target of PZQ is unclear, which make it difficult to find drug candidate with novel structure for schistosomiasis

  8. The way to dig out the drug leads Screen from old compounds:

  9. Find PZQ analogues as drug leads

  10. Big difference

  11. A: control, no drug, only DMSO C: PZQ B: compound P96

  12. Table 2. In vivo activity against different stages of S. japonicum in mice

  13. Table 3..In vivo activity in mice against juvenile S. japonicumat different doses of compound P96 (single oral administration)..

  14. Table 4.Cross-resistance study of compound P96

  15. Table 5.In vivo activityin rabbitagainst juvenile and adult S. japonicum of compound P96

  16. Figure 1. Growth inhibition of PZQ and compound P96 to normal human liver line (L02)

  17. Other preclinical study of P96 as a drug candidate are under going

  18. Research group

More Related